Ansell Limited Acquires a Minority Share in Yulex Corporation
Ansell Limited announces that it has purchased a minority share of Yulex Corporation, a manufacturer of biopolymers derived from guayule. The investment is not expected to have any material impact on Ansell's earnings per share in fiscal years 2012 and 2013.
Further, Ansell and Yulex executed an exclusive agreement for the global development, manufacturing and distribution rights for medical gloves, personal protective equipment gloves, and condoms made of guayule latex.
Guayule (Parthenium argentatum) is a commercial crop (a small evergreen shrub) and the only rubber-producing species other than the Brazilian rubber tree (Hevea brasiliensis) that has been used for latex production on a commercial scale. Extensive scientific research suggests that guayule latex does not produce allergic reactions with natural rubber latex sensitive individuals. Â
Magnus Nicolin, CEO of Ansell Limited notes, "Our agreements with Yulex are an important step in our strategy to accelerate the development of new innovative products while reducing our usage of rubber tree latex."Â
"We are pleased to be partnering with Ansell," says Yulex Corporation CEO Jeff Martin. "Our collaboration will advance the acceptance of guayule natural rubber as a U.S. biobased alternative for natural rubber and petroleum-based rubber products.  We are committed to developing 'green' renewable technologies for consumer and healthcare markets."
Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
